

Table SI. Comorbidity and cardiotoxicity of patients treated with *EGFR* inhibitors, *ALK/ROS1* inhibitors and anti-*VEGF* therapy.

Variable	Comorbidity group				P-value
	None	Cardiac	Other	Total ^a	
<i>EGFR</i> inhibitors, n (%)					
Overall					0.054
Comorbidity	40	88	346	474	
Cardiotoxicity	0	3 (3.4)	2 (0.6)	5 (1.1)	
Osimertinib					
Comorbidity	11	32	121	164	0.018
Cardiotoxicity	0	3 (9.4)	1 (0.8)	4 (2.4)	
<i>ALK/ROS1</i> inhibitors, n (%)					
Comorbidity	7	19	48	74	0.001
Cardiotoxicity	0	6 (30.0)	1 (2.1)	7 (9.5)	
Anti- <i>VEGF</i> therapy, n (%)					
Overall					0.614
Comorbidity	27	39	185	251	
Cardiotoxicity	0	1 (2.6)	2 (1.1)	3 (1.2)	
Bevacizumab					
Comorbidity	26	37	170	233	0.397
Cardiotoxicity	0	1 (2.7)	1 (0.6)	2 (0.9)	
Other targeted drugs only, n					
Comorbidity	1	1	4	6	-
Cardiotoxicity	0	0	0	0	

^aThe sum of the numbers was more than the total number of enrolled patients as 329 of 701 the patients received >1 targeted drug. χ^2 test and Fisher's exact test were used for statistical analysis. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; ROS1, c-ros oncogene 1; VEGFR, vascular endothelial growth factor receptor.